Ventyx Biosciences (VTYX) said Tuesday it is expanding its phase 2 study of VTX2735 in patients with recurrent pericarditis into Canada, the EU and the UK.
The expansion will allow Ventyx to introduce dose-ranging studies with the once-daily formulation of the current study, in preparation for a global phase 3 development plan, the company said.
Ventyx said that interim analysis for the ongoing phase 2 study will be presented as part of its R&D day in Q1 of 2026.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.